Rybrevant® (amivantamab-vmjw)
for Lung Cancer

Rybrevant (amivantamab-vmjw) is a targeted therapy for adults with metastatic or locally advanced non-small cell lung cancer (NSCLC) with certain abnormal EGFR genes. It targets EGFR and MET receptors to block cancer growth. It’s used alone or with lazertinib, carboplatin, and pemetrexed, depending on the EGFR mutation type (exon 19, 21, or 20 insertions), and may follow or replace prior treatments when the cancer progresses.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Lung Cancer